• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

四氢尿苷:人体中的生理处置及其对阿糖胞苷脱氨基作用的影响。

Tetrahydrouridine: Physiologic disposition and effect upon deamination of cytosine arabinoside in man.

作者信息

Kreis W, Woodcock T M, Gordon C S, Krakoff I H

出版信息

Cancer Treat Rep. 1977 Oct;61(7):1347-53.

PMID:589600
Abstract

[14C]-tetrahydrouridine (THU), a strong inhibitor of cytidine (CR) deaminase, was, after iv administration, rapidly and quantitatively cleared from the blood with a plasma half-life of about 1 hour. The main pathway of excretion was through the kidneys: most of a dose of 50 mg/kg was excreted within 12 hours and excretion was essentially complete within 48 hours. Oral administration of the same dose revealed absorption of about 10% from the gastrointestinal tract. THU at 10, 25, and 50 mg/kg given 15 minutes before [3H]-cytosine arabinoside (ara-C) at a dose of 0.003 mg/kg produced about a two fold increase in ara-C blood levels at all times measured from 5 minutes to 4 hours, with only slight increases in the half-life of ara-C. A dose-related effect of THU upon the deamination of ara-C was obvious only during the time from 15 minutes to 1 hour after the injection of 3H-ara-C. The inhibitory effect of THU upon CR deaminase was also reflected in a considerably increased ratio of ara-C/uracil arabinoside in the urine.

摘要

[14C] - 四氢尿苷(THU)是胞苷(CR)脱氨酶的强效抑制剂,静脉注射后,它能迅速且定量地从血液中清除,血浆半衰期约为1小时。排泄的主要途径是通过肾脏:50mg/kg剂量的大部分在12小时内排出,48小时内排泄基本完成。口服相同剂量时,胃肠道吸收约10%。在给予0.003mg/kg剂量的[3H] - 阿糖胞苷(ara - C)前15分钟,分别给予10mg/kg、25mg/kg和50mg/kg的THU,在5分钟至4小时的所有测量时间点,ara - C的血药浓度均升高约两倍,而ara - C的半衰期仅略有增加。仅在注射3H - ara - C后15分钟至1小时内,THU对ara - C脱氨的剂量相关效应明显。THU对CR脱氨酶的抑制作用还体现在尿中ara - C/阿糖尿苷的比例显著增加。

相似文献

1
Tetrahydrouridine: Physiologic disposition and effect upon deamination of cytosine arabinoside in man.四氢尿苷:人体中的生理处置及其对阿糖胞苷脱氨基作用的影响。
Cancer Treat Rep. 1977 Oct;61(7):1347-53.
2
Combinations of tetrahydrouridine and cytosine arabinoside in mouse tumors.四氢尿苷与阿糖胞苷在小鼠肿瘤中的联合应用。
Cancer Treat Rep. 1977 Oct;61(7):1355-64.
3
Pharmacology of combination chemotherapy of cytosine arabinoside (ara-C) and uracil arabinoside (ara-U) or tetrahydrouridine (THU) against murine leukemia L1210/0 in tumor-bearing mice.阿糖胞苷(ara-C)与阿糖尿苷(ara-U)或四氢尿苷(THU)联合化疗对荷瘤小鼠体内鼠白血病L1210/0的药理作用。
Cancer Invest. 1987;5(4):293-9.
4
Influence of tetrahydrouridine on the pharmacokinetics of intrathecally administered 1-beta-D-arabinofuranosylcytosine.四氢尿苷对鞘内注射1-β-D-阿拉伯呋喃糖基胞嘧啶药代动力学的影响。
Cancer Res. 1982 May;42(5):1736-9.
5
Phase I evaluation of tetrahydrouridine combined with cytosine arabinoside.四氢尿苷联合阿糖胞苷的I期评估
Cancer Treat Rep. 1979 Aug;63(8):1245-9.
6
Effect of tetrahydrouridine on the clinical pharmacology of 1-beta-D-arabinofuranosylcytosine when both drugs are coinfused over three hours.当两种药物在三小时内共同输注时,四氢尿苷对1-β-D-阿拉伯呋喃糖基胞嘧啶临床药理学的影响。
Cancer Res. 1988 Mar 1;48(5):1337-42.
7
Ara-C metabolism: implications for drug resistance and drug interactions.阿糖胞苷代谢:对耐药性和药物相互作用的影响
Bull Cancer. 1979;66(1):89-92.
8
Effect of tetrahydrouridine on the action of 1-beta-D-arabinofuranosylcytosine in synchronized cultures of normal rat kidney cells.四氢尿苷对正常大鼠肾细胞同步培养物中1-β-D-阿拉伯呋喃糖基胞嘧啶作用的影响。
Cancer Res. 1979 Oct;39(10):3981-5.
9
Pharmacokinetic considerations in evaluating the effects of tetrahydrouridine on 5-azacytidine chemotherapy in L1210 leukemic mice.评估四氢尿苷对L1210白血病小鼠5-氮杂胞苷化疗效果时的药代动力学考量
Cancer Treat Rep. 1978 Jul;62(7):1025-32.
10
Therapy of refractory/relapsed acute leukemia with cytosine arabinoside plus tetrahydrouridine (an inhibitor of cytidine deaminase)--a pilot study.阿糖胞苷联合四氢尿苷(一种胞苷脱氨酶抑制剂)治疗难治性/复发性急性白血病——一项初步研究。
Leukemia. 1991 Nov;5(11):991-8.

引用本文的文献

1
Fetal Hemoglobin Induction by Epigenetic Drugs.通过表观遗传药物诱导胎儿血红蛋白
Semin Hematol. 2018 Apr;55(2):60-67. doi: 10.1053/j.seminhematol.2018.04.008. Epub 2018 Apr 22.
2
Oral tetrahydrouridine and decitabine for non-cytotoxic epigenetic gene regulation in sickle cell disease: A randomized phase 1 study.口服四氢尿苷和地西他滨用于镰状细胞病的非细胞毒性表观遗传基因调控:一项随机1期研究。
PLoS Med. 2017 Sep 7;14(9):e1002382. doi: 10.1371/journal.pmed.1002382. eCollection 2017 Sep.
3
A phase I, pharmacokinetic, and pharmacodynamic evaluation of the DNA methyltransferase inhibitor 5-fluoro-2'-deoxycytidine, administered with tetrahydrouridine.
DNA甲基转移酶抑制剂5-氟-2'-脱氧胞苷与四氢尿苷联合给药的I期药代动力学和药效学评价
Cancer Chemother Pharmacol. 2015 Mar;75(3):537-46. doi: 10.1007/s00280-014-2674-7. Epub 2015 Jan 8.
4
High cytidine deaminase expression in the liver provides sanctuary for cancer cells from decitabine treatment effects.肝脏中高表达的胞苷脱氨酶为癌细胞提供了免受地西他滨治疗影响的庇护所。
Oncotarget. 2012 Oct;3(10):1137-45. doi: 10.18632/oncotarget.597.
5
Effects of tetrahydrouridine on pharmacokinetics and pharmacodynamics of oral decitabine.四氢尿苷对口服地西他滨药代动力学和药效学的影响。
Blood. 2012 Feb 2;119(5):1240-7. doi: 10.1182/blood-2011-08-371690. Epub 2011 Dec 7.
6
Plasma pharmacokinetics and oral bioavailability of the 3,4,5,6-tetrahydrouridine (THU) prodrug, triacetyl-THU (taTHU), in mice.血浆药代动力学和 3,4,5,6-四氢尿苷(THU)前药三乙酰基-THU(taTHU)在小鼠体内的口服生物利用度。
Cancer Chemother Pharmacol. 2011 Feb;67(2):421-30. doi: 10.1007/s00280-010-1337-6. Epub 2010 May 5.
7
Plasma pharmacokinetics and oral bioavailability of 3,4,5,6-tetrahydrouridine, a cytidine deaminase inhibitor, in mice.胞苷脱氨酶抑制剂3,4,5,6-四氢尿苷在小鼠体内的血浆药代动力学及口服生物利用度
Cancer Chemother Pharmacol. 2008 Aug;62(3):457-64. doi: 10.1007/s00280-007-0625-2. Epub 2007 Nov 15.
8
Antitumor activity and pharmacology of 1-beta-D-arabinofuranosylcytosine-5'-stearylphosphate: an orally active derivative of 1-beta-D-arabinofuranosylcytosine.1-β-D-阿拉伯呋喃糖基胞嘧啶-5'-硬脂酰磷酸酯的抗肿瘤活性与药理学:1-β-D-阿拉伯呋喃糖基胞嘧啶的一种口服活性衍生物
Jpn J Cancer Res. 1989 Jul;80(7):679-85. doi: 10.1111/j.1349-7006.1989.tb01696.x.
9
Pharmacokinetic drug interactions of commonly used anticancer drugs.常用抗癌药物的药代动力学药物相互作用。
Clin Pharmacokinet. 1986 May-Jun;11(3):223-35. doi: 10.2165/00003088-198611030-00004.
10
The role of deoxycytidine-metabolizing enzymes in the cytotoxicity induced by 3'-amino-2',3'-dideoxycytidine and cytosine arabinoside.脱氧胞苷代谢酶在3'-氨基-2',3'-二脱氧胞苷和阿糖胞苷诱导的细胞毒性中的作用。
Cancer Chemother Pharmacol. 1992;30(2):139-44. doi: 10.1007/BF00686406.